AJR Am J Roentgenol

1. SALINAS-MIRANDA E, Birosh A, Mcinnes MDF, Breau RH, et al
   NPV of Biparametric and Multiparametric Prostate MRI: A Comparative Systematic Review and Meta-Analysis.
   AJR Am J Roentgenol. 2025 Mar 5. doi: 10.2214/AJR.24.32328.
   

   >> Share

   
   

   
   BJU Int

2. TOH EA, White J, Clarke J, Hider P, et al
   Variation in prostate cancer assessment and management between Maori and non-Maori in New Zealand.
   BJU Int. 2025 Jun 13. doi: 10.1111/bju.16805.
   

   >> Share

   
   
3. FLETCHER SA, Alshak MN, Lee S, Singla N, et al
   Clinically significant prostate cancer detected by systematic biopsy in patients with MRI lesions.
   BJU Int. 2025 Jun 12. doi: 10.1111/bju.16816.
   

   >> Share

   
   

   
   BMC Cancer

4. ZHANG G, Guo X, Zhu C, Li S, et al
   Association between serum 25-hydroxyvitamin D and prostate cancer in middle-aged and elderly Americans: a national population-based analysis of NHANES 2001-2018.
   BMC Cancer. 2025;25:1014.
   

   >> Share

   
   

   
   Eur J Radiol

5. SHIN JI, Park KJ, Park MY, Kim MH, et al
   Diagnostic performance of biparametric MRI according to prostate imaging quality (PI-QUAL) version 2: Analysis of Multi-Institutional Data.
   Eur J Radiol. 2025;189:112209.
   

   >> Share

   
   

   
   Eur Radiol

6. FRANSEN SJ, Bosma JS, van Lohuizen Q, Roest C, et al
   Simulating workload reduction with an AI-based prostate cancer detection pathway using a prediction uncertainty metric.
   Eur Radiol. 2025 Jun 7. doi: 10.1007/s00330-025-11727.
   

   >> Share

   
   

   
   Eur Urol

7. KRISTIANSEN G, Paner GP, Shah RB
   Reply to Matthew R. Cooperberg, Jeremy Grummet, and Scott E. Eggener's Letter to the Editor re: Rajal B. Shah, Gladell P. Paner, Liang Cheng, et al. Genitourinary Pathology Society and International Society of Urological Pathology White Paper on Defin
   Eur Urol. 2025 Jun 7:S0302-2838(25)00330-6. doi: 10.1016/j.eururo.2025.
   

   >> Share

   
   
8. SHERRYN S, Baskoro B, Sun J
   Re: Veeru Kasivisvanathan, Vinson Wai-Shun Chan, Keiran D. Clement, et al. An Individual Patient Data Meta-analysis of Randomised Trials Comparing Magnetic Resonance Imaging Targeted Biopsy with Standard Transrectal Ultrasound Guided Biopsy in the Det
   Eur Urol. 2025 Jun 7:S0302-2838(25)00332-X. doi: 10.1016/j.eururo.2025.
   

   >> Share

   
   
9. ALBERTSEN P
   Re: Assessment of a Polygenic Risk Score in Screening for Prostate Cancer.
   Eur Urol. 2025 Jun 6:S0302-2838(25)00328-8. doi: 10.1016/j.eururo.2025.
   

   >> Share

   
   

   
   Int J Radiat Oncol Biol Phys

10. VAN WERKHOVEN LA, Milder MTW, Hoogeman MS, van Werkhoven E, et al
    Results of a Single-Arm Phase 2 Clinical Trial: Online Adaptive Stereotactic Body Radiation Therapy for Abdominal-Pelvic Oligometastases.
    Int J Radiat Oncol Biol Phys. 2025;122:729-738.
    

    >> Share

    
    
11. HOWARD TP, Ferguson D, Han Z, Mamon HJ, et al
    Magnetic Resonance-Guided Stereotactic Body Radiation Therapy With Daily Online Plan Adaptation for Reirradiation in the Abdomen.
    Int J Radiat Oncol Biol Phys. 2025;122:752-759.
    

    >> Share

    
    
12. COURTNEY PT, Dong H, Lao Y, Pham J, et al
    Dosimetric Comparison of MRI-Guided Versus Reduced Margin CT-Guided Stereotactic Body Radiotherapy for Localized Prostate Cancer: Post-Hoc Analysis of a Phase III Trial.
    Int J Radiat Oncol Biol Phys. 2025 Jun 5:S0360-3016(25)00553.
    

    >> Share

    
    

    
    Int J Urol

13. KIMURA Y, Honda M, Yamane H, Shimizu R, et al
    Outcomes in Health-Related Quality of Life and Impact of Urinary Incontinence on Health-Related Quality of Life 7 Years After Robot-Assisted Radical Prostatectomy.
    Int J Urol. 2025;32:664-671.
    

    >> Share

    
    
14. FALKENBACH F, Penaranda NR, Longoni M, Marmiroli A, et al
    The Effect of Chronic Kidney Disease on Adverse In-Hospital Outcomes at Radical Prostatectomy.
    Int J Urol. 2025;32:710-717.
    

    >> Share

    
    
15. OKUDA Y, Kato T, Ishizuya Y, Hayashi T, et al
    PARP Inhibitors in Genitourinary Cancer: A New Paradigm Beyond Prostate Cancer.
    Int J Urol. 2025 Jun 9. doi: 10.1111/iju.70100.
    

    >> Share

    
    

    
    J Natl Cancer Inst

16. 
    Correction to: The association of where patients with prostate cancer live and receive care on racial treatment inequities.
    J Natl Cancer Inst. 2025 Jun 13:djaf142. doi: 10.1093.
    

    >> Share

    
    
17. SCILIPOTI P, Garmo H, Gedeborg R, Robinson D, et al
    Incidence and prognostic implications of prostate-specific antigen persistence and relapse after radical prostatectomy: population-based study.
    J Natl Cancer Inst. 2025;117:1142-1150.
    

    >> Share

    
    

    
    J Nucl Med

18. MOGENSEN AW, Torp-Pedersen C, Norgaard M, Petersen LJ, et al
    The Use of PSMA PET/CT Improves Overall Survival in Men with Biochemically Recurrent Prostate Cancer Treated with Salvage Radiotherapy: Real-World Data from an Entire Country.
    J Nucl Med. 2025 Jun 12:jnumed.125.269996. doi: 10.2967/jnumed.125.269996.
    

    >> Share

    
    
19. BOBBA KN, Wadhwa A, Bidkar AP, Raveendran A, et al
    Evaluation of (134)Ce/(134)La-PSMA-617 for PET Imaging and Auger Electron Therapy of Prostate Cancer.
    J Nucl Med. 2025 Jun 12:jnumed.125.269751. doi: 10.2967/jnumed.125.269751.
    

    >> Share

    
    

    
    J Urol

20. LUO H, Guo J, Li H, Su H, et al
    Letter: Restriction Spectrum Imaging as a Quantitative Biomarker for Prostate Cancer With Reliable Positive Predictive Value.
    J Urol. 2025 Jun 10:101097JU0000000000004624. doi: 10.1097/JU.0000000000004624.
    

    >> Share

    
    
21. KAPLAN-MARANS E
    Letter: Prostate-Specific Antigen Density to Select Magnetic Resonance Imaging-Targeted vs Combined Biopsy for Prostate Cancer Diagnosis: A Secondary Analysis of the Trio Study.
    J Urol. 2025 Jun 10:101097JU0000000000004625. doi: 10.1097/JU.0000000000004625.
    

    >> Share

    
    
22. WEI JT, Barocas D, Carlsson S, Coakley F, et al
    Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening: Erratum.
    J Urol. 2025;214:111.
    

    >> Share

    
    
23. NI X, Sui J, Wang B, Wang H, et al
    Lower Testosterone level and metastases-free survival in nmCRPC patients treated with novel antiandrogens: A post-hoc analysis of SPARTAN and ARAMIS.
    J Urol. 2025 Mar 25:101097JU0000000000004545. doi: 10.1097/JU.0000000000004545.
    

    >> Share

    
    

    
    Nat Rev Urol

24. TAO Q, Zhang Q
    Translating the m(6)A epitranscriptome for prostate cancer.
    Nat Rev Urol. 2025 Jun 9. doi: 10.1038/s41585-025-01054.
    

    >> Share

    
    

    
    PLoS One

25. LIU J, Liu X, Zeng H, Tong Y, et al
    Severe cutaneous adverse reactions associated with second-generation androgen receptor antagonists in prostate cancer patients.
    PLoS One. 2025;20:e0325448.
    

    >> Share

    
    
26. DI PAOLA FJ, Cardoso LH, Nikitopoulou E, Kulik B, et al
    Impact of mtG3PDH inhibitors on proliferation and metabolism of androgen receptor-negative prostate cancer cells: Role of extracellular pyruvate.
    PLoS One. 2025;20:e0325509.
    

    >> Share

    
    

    
    Prostate

27. HORVATH A, Blasszauer C, Komka I, Reibl D, et al
    Real-World Overall Survival Comparison of Enzalutamide and Abiraterone In First- and Second-Line Setting of Metastatic Castration-Resistant Prostate Cancer.
    Prostate. 2025 Jun 8. doi: 10.1002/pros.24923.
    

    >> Share

    
    
28. FUKUSHIMA T, Goto K, Nakano Y, Tasaka S, et al
    Comprehensive Genomic Profiling Testing for Castration-Resistant Prostate Cancer in Advanced Elderly Patients: A Single-Center Retrospective Cohort Study.
    Prostate. 2025 Jun 10. doi: 10.1002/pros.24926.
    

    >> Share

    
    
29. YANG YJ, Zeng C, Schaffer KR, Tran TC, et al
    Hormone Therapy Usage Is Associated With Adverse Cardiovascular Events in Prostate Cancer Patients of the All of Us Research Program Cohort.
    Prostate. 2025 Jun 11. doi: 10.1002/pros.24913.
    

    >> Share

    
    
30. LEMSTER AL, Grunhagen S, Schmalfeld S, Lenz F, et al
    Downregulation of NONO Suppresses Proliferation, Migration, and Invasion in Metastatic Prostate Cancer.
    Prostate. 2025 Jun 12. doi: 10.1002/pros.24925.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share